Investigation Report on Chinese Deproteinized Calf Blood Extractives Market, 2018-2022

Choose License

Description
Deproteinized Calf Blood Extractives, as a drug that improves the energy metabolism of cells, has aroused wide concern at home and abroad after years of clinical application because of its prominent curative effect on the nervous system. At present, the clinical applications mainly include cerebral and nervous system diseases, vascular diseases, ulcer diseases, burns, etc. 
The global growth of patented nervous system drugs is slowing down. The drugs used to treat cranial nerve and cerebral circulation systems are experiencing a market downturn. However, the market performance is quite different in China. In recent years, the drug demand from neurology departments of Chinese hospitals is growing continuously with the rapid development of the pathogenesis of common neurological diseases and clinical pharmacology. Deproteinized Calf Blood Extractives is a big variety and also a pillar nervous system drug in clinical applications in China. 
According to CRI, the sales value of Deproteinized Calf Blood Extractives exceeded CNY 1 billion in 2017. The market was dominated by Jinzhou Ahon Pharmaceuticals Co., Ltd., Harbin Sanctity Pharmaceutical Co., Ltd., Jilin Connell Pharmaceutical Co., Ltd., Wuhan Humanwell Pharmaceutical Co., Ltd., etc., with CR5 reaching over 90%. Jinzhou Ahon Pharmaceuticals Co., Ltd. captured the biggest market share, whose market share exceeded 70% by sales value in 2017.
Injections account for over 90% of the sales value while the market shares of gels and eye drops are less than 5% in total. 
CRI expects that the Chinese Deproteinized Calf Blood Extractives market still has some growth potential from 2018 to 2022. 

Topics Covered: 
-Development environment of the Chinese Deproteinized Calf Blood Extractives market
-Size of the Chinese Deproteinized Calf Blood Extractives market
-Competition pattern of the Chinese Deproteinized Calf Blood Extractives market
-Prices in the Chinese Deproteinized Calf Blood Extractives market
-Forecast on the Chinese Deproteinized Calf Blood Extractives market
Table of Contents
1 Relevant Concepts of Deproteinized Calf Blood Extractives
1.1 Indications
1.2 Development History of Deproteinized Calf Blood Extractives in China
1.3 Governmental Approval of Deproteinized Calf Blood Extractives in China

2 Overview of Chinese Deproteinized Calf Blood Extractives Market, 2013-2017
2.1 Sales Value of Deproteinized Calf Blood Extractives in China
2.1.1 Overall Sales Value
2.1.2 Sales Value in Different Regions
2.2 Sales Volume of Deproteinized Calf Blood Extractives in China
2.2.1 Overall Sales Volume
2.2.2 Sales Volume in Different Regions
2.3 Market Shares of Deproteinized Calf Blood Extractives in Different Dosage Forms
2.3.1 Injections
2.3.2 Gels
2.3.3 Eye Drops

3 Analysis on Major Deproteinized Calf Blood Extractives Manufacturers in China, 2013-2018
3.1 Market Competition
3.1.1 Market Shares by Sales Value
3. 1.2 Market Shares by Sales Volume
3.2 Jinzhou Ahon Pharmaceuticals Co., Ltd. 
3.2.1 Enterprise Profile
3.2.2 Sales of Jinzhou Ahon's Deproteinized Calf Blood Extractives
3.2.3 Sales Price of Jinzhou Ahon's Deproteinized Calf Blood Extractives
3.3 Harbin Sanctity Pharmaceutical Co., Ltd. 
3.4 Jilin Connell Pharmaceutical Co., Ltd. 
3.5 Wuhan Humanwell Pharmaceutical Co., Ltd. 
3.6 Shenyang Xingqi Pharmaceutical Co., Ltd. 
3.7 Heilongjiang Jiangshi Pharmaceutical Co., Ltd. 
3.8 Nycomed 
3.9 Zhaoke Pharmaceutical (Hefei) Co. Ltd. 
3.10 Changchun Tiancheng Pharmaceutical Co., Ltd. 
3.11 Fuan Pharmaceutical Group Hubei People's Pharmaceutical Co., Ltd. 

4 Prospects of Chinese Deproteinized Calf Blood Extractives Market, 2018-2022
4.1 Forecast on Market Size
4.2 Forecast on Competition Pattern

Selected Charts
Chart Patents of Deproteinized Calf Blood Extractives in China
Chart Governmental Approval of Deproteinized Calf Blood Extractives in China
Chart Sales of Deproteinized Calf Blood Extractives in China
Chart Sales Value of Deproteinized Calf Blood Extractives in China, 2013-2017
Chart Sales Value of Deproteinized Calf Blood Extractives in Parts of China, 2013-2017
Chart Sales Volume of Deproteinized Calf Blood Extractives in China, 2013-2017
Chart Sales Volume of Deproteinized Calf Blood Extractives in Parts of China, 2013-2017
Chart Market Shares of Top 10 Deproteinized Calf Blood Extractives Manufacturers by Sales Value, 2013-2017
Chart Market Share and Sales Value of Jinzhou Ahon's Deproteinized Calf Blood Extractives in China, 2013-2017
Chart Market Share and Sales Value of Heilongjiang Jiangshi's Deproteinized Calf Blood Extractives in China, 2013-2017
Chart Market Shares of Top 5 Deproteinized Calf Blood Extractives Manufacturers by Sales Volume, 2013-2017
Chart Sales Value and Market Share of Deproteinized Calf Blood Extractives Injections, 2013-2017
Chart Sales Value and Market Share of Deproteinized Calf Blood Extractives Gels, 2013-2017
Chart Sales Value and Market Share of Deproteinized Calf Blood Extractives Eye Drops, 2013-2017
Chart Prices of Jinzhou Ahon's Deproteinized Calf Blood Extractives in Several Chinese Cities, 2017-2018
Chart Prices of Harbin Sanctity's Deproteinized Calf Blood Extractives in Several Chinese Cities, 2017-2018
Chart Prices of Heilongjiang Jiangshi's Deproteinized Calf Blood Extractives in Several Chinese Cities, 2017-2018
Chart Prices of Jilin Connell's Deproteinized Calf Blood Extractives in Several Chinese Cities, 2017-2018
Chart Forecast on Sales of Deproteinized Calf Blood Extractives in China, 2018-2022


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by China Research and Intelligence

Investigation Report on China's Basiliximab Market, 2019-2023

Description In China, 10.80% or about 150 million people have chronic kidney disease, and over 3 million of them have end-stage renal disease, i.e. uremia. According to CRI, the incidence of chronic kidney disease in China stays at a high level in re...

Investigation Report on China's Diclofenac Market, 2019-2023

Description Rheumatoid arthritis is a common frequently-occurring disease. According to the 2018 Chinese Guideline for the Diagnosis and Treatment of Rheumatoid Arthritis, in 2018, a total of 5 million people in China had rheumatoid arthritis. As an ...

Investigation Report on China's Polyene Phosphatidylcholine Market, 2019-2023

Description According to statistics, at the end of 2018, there were about 86 million hepatitis B carriers and about 10 million hepatitis C carriers in China. In 2014, the prevalence of hepatitis B surface antigen in children under five years of age d...

Investigation Report on China's Recombinant Follitropin Beta Market, 2019-2023

Description In China, the number of infertile couples is increasing. According to Chinese media, in 2018, more than 40 million people in China were infertile, with the incidence of infertility in couples of childbearing age increasing from 3% 20 year...

Investigation Report on China's Recombinant Human Endostatin Market, 2019-2023

Description In 2008, lung cancer replaced liver cancer to be the malignant tumor with the highest fatality rate in China. Over the past 30 years, lung cancer has become a heavy burden on the Chinese people and society. In 2017, the number of lung can...

New Pharmaceuticals and Healthcare Reports